{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:36:31Z","timestamp":1761492991514,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jcjd.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T13:00:17Z","timestamp":1496840417000},"page":"469-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["So Many Antihyperglycemics: How to Choose? A Practical Approach"],"prefix":"10.1016","volume":"41","author":[{"given":"Alice Y.Y.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2017.04.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjd.2013.01.016","article-title":"Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada: Targets for glycemic control","volume":"37","author":"Imran","year":"2013","journal-title":"Can J Diabetes"},{"issue":"Suppl. 1","key":"10.1016\/j.jcjd.2017.04.001_bib0015","first-page":"S1","article-title":"Standards of medical care in diabetes. 2017","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"issue":"Suppl. 2","key":"10.1016\/j.jcjd.2017.04.001_bib0020","article-title":"Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0025","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jcjd.2016.09.003","article-title":"Pharmacologic management of type 2 diabetes: 2016 interim update","volume":"40","author":"Booth","year":"2016","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.2016.9400","article-title":"Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: A meta-analysis","volume":"316","author":"Palmer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.diabres.2016.04.037","article-title":"Triple therapy combinations for the treatment of type 2 diabetes: A network meta-analysis","volume":"116","author":"Lee","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0045","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","article-title":"Combinaton of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"The ORIGIN Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0065","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study: A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0070","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicenter, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0075","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0080","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0085","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0090","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0095","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc15-0764","article-title":"Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: An observational study","volume":"39","author":"Fu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0100","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0110","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0115","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0120","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: A \u201cthrify substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"year":"2016","series-title":"Insights in the findings: Mediation analysis (results)","author":"Inzucchi","key":"10.1016\/j.jcjd.2017.04.001_bib0125"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s13300-016-0197-4","article-title":"Follow the LEADER: Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results trial","volume":"7","author":"Kalra","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcjd.2015.05.009","article-title":"Pharmacologic management of type 2 diabetes: 2015 interim update","volume":"29","author":"Harper","year":"2015","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2017.04.001_bib0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267117300680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267117300680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:29:39Z","timestamp":1761492579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267117300680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1499267117300680"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2017.04.001","relation":{},"ISSN":["1499-2671"],"issn-type":[{"type":"print","value":"1499-2671"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"So Many Antihyperglycemics: How to Choose? A Practical Approach","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Canadian Diabetes Association.","name":"copyright","label":"Copyright"}]}}